Weekly Issue — 2026-01-04

The study, published in BMJ Open Diabetes Research & Care, followed 583 adults from a Hong Kong workforce cohort first assessed between 1998 and 2003 and reassessed roughly 12 years later. About 40% of them had a family history of young-onset type 2 diabetes (a parent or sibling diagnosed before age 40), a group the researchers call FmH-YOD. The question: does adding a 1-hour glucose reading from a standard OGTT meaningfully sharpen prediction in that high-risk group, the way it does in the general population?

The answer, per the Hong Kong analysis, is more nuanced than the wellness shorthand suggests. Both family history and a high 1-hour glucose independently predicted who'd later develop diabetes — but the two risk factors interacted negatively, meaning the predictive bang you get from adding a 1-hour reading is smaller in the family-history group than in everyone else. Practically speaking: when your baseline risk is already loaded by genetics, the fancier test buys you less new information.

Among the 583 participants — median age 41, mostly lean by Western standards with a median BMI of 23.3 — 99 (about 17%) had developed diabetes by follow-up. Split them by family history and the picture sharpens. In the family-history group, 45% of those with a high 1-hour glucose progressed to diabetes, versus 17% of those with a normal 1-hour glucose. In the no-family-history group, the same split was 16% versus 1.8%, according to the study.

Notice what jumps out: a family-history participant with a normal 1-hour glucose still had a 17% chance of developing diabetes — roughly the same risk as someone without family history but with an elevated 1-hour reading. In other words, a reassuring OGTT result didn't reassure very much in the high-risk group. The genetics were doing a lot of the talking.

That's where fasting glucose re-enters the chat. In the receiver-operating-characteristic analysis the authors ran to compare tests head-to-head, the 1-hour glucose's discriminative performance dropped in the family-history subgroup, while plain fasting plasma glucose outperformed it for predicting incident diabetes in that same group. The older, cheaper, less-trendy measurement won where it arguably matters most.

A few honest caveats before anyone reorganizes their next physical. This is a single observational cohort of fewer than 600 people, drawn from one Hong Kong workforce, and the confidence intervals around some of the headline odds ratios are wide — the combined family-history-plus-high-1-hour group, for instance, carried a 28-fold odds of incident diabetes but with a confidence interval spanning roughly 5 to 146, per the published estimates. That's a strong signal with imprecise edges.

It also doesn't mean the 1-hour OGTT is overrated in general. International groups have been pushing the test precisely because it catches dysglycemia that fasting numbers miss in average-risk adults — and this study doesn't contradict that. What it does suggest is that which test is most informative depends on who's being tested. Add strong family history and the calculus shifts.

There's a tidy logic to it. A 1-hour glucose spike is largely a story about how your pancreas and tissues handle a sugar load right now. A fasting number is closer to a long-run summary of your baseline metabolism. In people whose biology is already nudged toward early diabetes by inherited factors, that baseline drift may simply show up earlier — and more legibly — in a fasting draw.

The takeaway isn't to skip any test, and it certainly isn't to self-diagnose from a single number. It's to know which questions you're actually asking your bloodwork to answer. If a parent or sibling was diagnosed with type 2 diabetes before 40, that fact is itself a major piece of information — and the new data suggest your fasting glucose deserves close attention rather than being dismissed as old-fashioned. A clinician who knows your family history is best placed to decide what to order, how often, and when to add hemoglobin A1c or an OGTT to the picture.

For everyone else, the broader point still holds: family history is data. So is a fasting number you've been ignoring on the lab printout because your 1-hour glucose looked fine.

I know. You came here for one thing and I'm already adding another. But stay with me, because this reframing is the kind of news that quietly takes pressure off — not adds to it. A 2025 review in the Journal of Clinical Gastroenterology lays out a practical framework for gastroenterologists treating MASLD, and the headline finding is striking: while MASLD is now the most common chronic liver disease in the world, the leading cause of death among people who have it isn't liver failure. It's cardiovascular disease.

That single fact rearranges the to-do list. If you're a parent juggling a toddler's breakfast and your own follow-up appointment, it means the work in front of you is less about protecting one organ and more about tending to the whole metabolic system the organ sits inside.

Names in medicine shape behavior. "Fatty liver" sounded like a lifestyle scolding; it focused attention on the organ and, often, on shame. MASLD — metabolic dysfunction-associated steatotic liver disease — points instead at the underlying biology: insulin resistance, disordered lipids, the cluster of conditions that tend to show up together. The review frames MASLD as the liver-side expression of a broader metabolic story, one that is strongly associated with type 2 diabetes, obesity, and hypertension.

That's why the authors argue that addressing metabolic health is a fundamental component of MASLD management, not an add-on. The liver responds when the system around it changes.

The review is written for gastroenterologists, but the logic translates for the rest of us. If MASLD travels with high blood sugar, extra weight around the middle, high blood pressure, and unhelpful cholesterol patterns, then the levers that move those numbers are the same ones that protect the liver. The authors describe a practical framework for integrating metabolic health optimization into routine MASLD care, including lifestyle changes and, when appropriate, medications — often in consultation with other specialists.

What this looks like for a busy parent is less dramatic than you might expect. It's the same handful of habits clinicians have been recommending for cardiometabolic health for years: regular movement that fits your week, meals built around fiber and protein, sleep when you can get it, and a real relationship with a clinician who tracks your numbers over time. The shift isn't a new regimen. It's understanding that those small habits are doing double duty — for your heart and your liver at once.

A few things worth naming. This is one clinical review, not a randomized trial, and it's written as practical guidance for specialists rather than a definitive verdict. The strong association the authors describe between MASLD and cardiovascular disease is well established in the literature they synthesize, but "associated with" is not the same as "caused by," and the right treatment plan for any individual depends on the rest of their health picture. The review's job is to frame the field; yours, with a clinician, is to translate that frame into something that fits your life.

What the evidence supports comfortably is the direction of travel: liver health and cardiometabolic health are not separate projects. Treating them as one is the current best thinking.

If reading this has left you with that familiar I-should-do-something feeling, here's the kindest version of that next step: don't try to overhaul anything. Pick one number you don't currently know — your blood pressure, your fasting glucose, your most recent lipid panel — and find it. Ask your clinician to walk you through it. If MASLD is on your chart, ask how it connects to the rest.

The shift the review is pointing at is less about doing more and more about seeing the whole picture. Your liver isn't a separate concern. It's part of the same system you've already been quietly looking after every time you went for a walk, drank water instead of soda, or chose the early night over the late scroll. That work counts. It just counts for more than you thought.

The study, published in the Israel Journal of Health Policy Research, mined the electronic medical records of one Israeli HMO across 2020 and 2021 — the years when remote visits stopped being a novelty and became infrastructure. Researchers sorted eligible patients into three buckets based on how they actually used their primary care: a face-to-face group (more than 60% in-person encounters), a remote group (more than 60% telemedicine), and a mixed group for everyone in between. Then they asked a deceptively simple question: who got referred for mammography, fecal occult blood testing (FOBT) and DEXA bone-density scans — and who actually went and did them?

The referral numbers are the first surprise. For mammography, referral rates were 27.3% in the predominantly face-to-face group versus 29.8% in the remote group and 32.9% in the mixed group. For FOBT, the pattern repeated: 55.6% face-to-face, 60.3% remote, 58.7% mixed. In other words, patients whose care leaned virtual were more likely to walk away with a screening order in hand, not less. That cuts against the easy narrative that telemedicine is inherently a preventive-care desert.

The wrinkle — and the reason this paper matters to anyone serious about a quantified preventive stack — is that a referral is not a result. The Israeli authors explicitly distinguish between whether a screening was referred and whether it was performed, and they signal that the two diverge across modalities for all three tests in their cohort. The full abstract is truncated mid-sentence on the public record, so the precise performance percentages for each group are not reproduced here; the takeaway the authors flag is that modality appears to shape the entire screening pipeline, not just the click that generates the order. For biohackers used to thinking in funnels, this is a familiar shape: top-of-funnel intent is the easy metric; downstream conversion is where the system actually fails.

The mechanism is intuitive once you sit with it. A video visit can absolutely surface a screening prompt — many EHRs nudge the clinician with an on-screen alert the moment the chart opens. But the in-person visit bundles the order with a physical handoff: a printed slip, a walk past the imaging desk, a nurse who books the appointment before the patient leaves. Remove the building, and you remove the choreography. The order exists; the follow-through is now homework.

The evidence here is best described as moderate and directional. This is a retrospective cohort study at a single Israeli HMO covering 2020 and 2021 — pandemic years, when both clinical workflows and patient behavior were anything but steady-state. Modality assignment was based on how patients actually used the system, not random allocation, so the remote and face-to-face groups likely differ in ways the study cannot fully control for: age, comorbidity burden, digital literacy, distance from a clinic. Healthcare systems outside Israel — with different reimbursement, different EHR nudges, different screening logistics — may produce different funnels entirely.

What the study does support is a structural point that the digital-health boom has been slow to internalize: preventive medicine is a logistics problem as much as a clinical one, and changing the venue of the visit changes the logistics. The headline-friendly framing — "telemedicine causes fewer screenings" — is too strong for what the published abstract actually shows. The more accurate framing is that virtual and in-person care produce different preventive-care funnels, and the gap between order and completion is where the system leaks.

For readers tracking the maturation of virtual primary care, the interesting frontier is not whether telemedicine "works" but whether the screening-completion gap can be engineered shut. The candidates are obvious if unproven: automated scheduling that books the mammogram inside the video visit itself; mail-out FOBT kits triggered the moment the order is signed; SMS nudges with a friction-free booking link; integration with retail imaging networks so a DEXA scan is as easy to schedule as a haircut. None of these are tested at scale against the modality gap the Israeli authors describe. They are hypotheses, not protocols.

The honest summary for an n-of-1 audience: if your primary care has shifted predominantly virtual, the cohort data suggest you may actually be slightly more likely to receive a screening referral — and that the meaningful variable is what happens after the video call ends. Talk to a clinician about which screenings are due for you, and treat the booking step as part of the visit, not an optional epilogue.